What the company actually pays, and whether its own cash supports it.
What stands out
Dividend several times the last twelve months' earnings
Dividends view
Yield
1.88%Below 5Y avg (3.40%)
Annual Rate
CNY 0.35Paid annual
Payout Ratio
357.9%High
Payback Period
36.3 yr
Last Ex-Dividend
May 27, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.01BCNY
1.20B · vs all stocks (USD)
Updated Oct 21, 2026
Trailing P/E
187.70x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Revenue (TTM)
2.61BCNY
391.82M · vs all stocks (USD)
Updated Oct 21, 2026
Profit Margin
1.55%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Beta
0.3050x
vs all stocks
Updated Oct 21, 2026
52-Week Change
37.76%
vs all stocks
Updated Oct 21, 2026
Market Capitalization
8.01BCNY
1.20B · vs all stocks (USD)
Updated Oct 21, 2026
Enterprise Value
6.26BCNY
938.45M · vs all stocks (USD)
Updated Oct 21, 2026
Trailing P/E
187.70x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Forward P/E
40.80x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Price to Sales (TTM)
3.08x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Price to Book (MRQ)
1.53x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Enterprise to Revenue
2.40x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Enterprise to EBITDA
19.88x
vs Medical Instruments & Supplies peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 29.33×.Updated Oct 21, 2026
Gross Margin
30.60%
vs Medical Instruments & Supplies peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 16.63%.Updated Oct 21, 2026
Profit Margin
1.55%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Operating Margin
20.07%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Return on Assets (TTM)
0.88%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Return on Equity (TTM)
0.69%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Revenue (TTM)
2.61BCNY
391.82M · vs all stocks (USD)
Updated Oct 21, 2026
Revenue per Share (TTM)
6.06CNYUpdated Oct 21, 2026
Quarterly Revenue Growth
44.10%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Gross Profit (TTM)
434.66MCNY
65.15M · vs all stocks (USD)
Updated Oct 21, 2026
EBITDA (TTM)
213.49MCNY
32.00M · vs all stocks (USD)
Updated Oct 21, 2026
Net Income (TTM)
40.52MCNY
6.07M · vs all stocks (USD)
Updated Oct 21, 2026
Quarterly Earnings Growth (YoY)
39.31%
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Operating Cash Flow (TTM)
247.01MCNY
37.02M · vs all stocks (USD)
Updated Oct 21, 2026
Levered Free Cash Flow (TTM)
-113.97MCNY
-17.08M · vs all stocks (USD)
Updated Oct 21, 2026
Trailing Annual Dividend Rate
0.3500CNYUpdated Oct 21, 2026
Trailing Annual Dividend Yield
1.88%
vs all stocks
Updated Oct 21, 2026
5-Year Average Dividend Yield
3.40%
vs all stocks
Updated Oct 21, 2026
Payout Ratio
357.87%
vs Medical Instruments & Supplies peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 350%.Updated Oct 21, 2026
Minority Interest (Equity)
160.99MCNYFY2025 · Dec 31, 2025
Revenue
2.37BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
2.11BCNYFY2025 · Dec 31, 2025
Gross Profit
264.58MCNYFY2025 · Dec 31, 2025
Operating Income
-53.29MCNY
-7.99M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-124.11MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-7.63MCNYFY2025 · Dec 31, 2025
Net Income
-116.48MCNYFY2025 · Dec 31, 2025
EBIT
-93.08MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
213.49MCNYFY2025 · Dec 31, 2025
Research & Development
51.08MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
81.80MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
25.48MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
45.41MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
31.03MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.2600CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.2600CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
432.24MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
432.24MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-116.48MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
4.09MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-109.25MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-299.24MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
1.19BCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-116.48MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
53.94MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
42.43MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
-89.14MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-189.98MCNYFY2025 · Dec 31, 2025
Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025
Purchase of Investments
-7.00BCNYFY2025 · Dec 31, 2025
Sale of Investments
7.56BCNYFY2025 · Dec 31, 2025
Other Investing Activity
8.88MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
377.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
1.15BCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-768.93MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-126.51MCNYFY2025 · Dec 31, 2025
Other Financing Charges
2.74MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
253.48MCNYFY2025 · Dec 31, 2025
Shares Outstanding
428.86MSharesUpdated Oct 21, 2026
Float Shares
117.02MSharesUpdated Oct 21, 2026
% Held by Insiders
73.15%
vs all stocks
Updated Oct 21, 2026
% Held by Institutions
0.46%
vs all stocks
Updated Oct 21, 2026
Total Cash (MRQ)
3.80BCNY
569.95M · vs all stocks (USD)
Updated Oct 21, 2026
Total Cash per Share (MRQ)
8.90CNYUpdated Oct 21, 2026
Total Debt (MRQ)
1.58BCNY
236.99M · vs all stocks (USD)
Updated Oct 21, 2026
Total Debt to Equity (MRQ)
0.2918x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Current Ratio (MRQ)
2.53x
vs Medical Instruments & Supplies peers
Updated Oct 21, 2026
Book Value per Share (MRQ)
12.30CNYUpdated Oct 21, 2026
Total Assets
7.44BCNY
1.11B · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
4.73BCNYFY2025 · Dec 31, 2025
Total Liabilities
2.02BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.71BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
253.44MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
1.76BCNYFY2025 · Dec 31, 2025
Cash
1.00BCNYFY2025 · Dec 31, 2025
Cash Equivalents
204.57MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
1.21BCNYFY2025 · Dec 31, 2025
Other Short-term Investments
1.88BCNYFY2025 · Dec 31, 2025
Accounts Receivable
401.59MCNYFY2025 · Dec 31, 2025
Inventory
623.59MCNYFY2025 · Dec 31, 2025
Accounts Payable
418.31MCNYFY2025 · Dec 31, 2025
Short-term Debt
1.12BCNYFY2025 · Dec 31, 2025
Other Current Liabilities
3.52MCNYFY2025 · Dec 31, 2025
Long-term Debt
227.80MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
428.86MCNYFY2025 · Dec 31, 2025
Retained Earnings
3.08BCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
5.42BCNY
812.66M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
18.99MCNYFY2025 · Dec 31, 2025
52-Week Low
9.21CNYUpdated Oct 21, 2026
52-Week High
25.91CNYUpdated Oct 21, 2026
52-Week Change
37.76%
vs all stocks
Updated Oct 21, 2026
Beta
0.3050x
vs all stocks
Updated Oct 21, 2026
50-Day MA
17.42CNYUpdated Oct 21, 2026
200-Day MA
14.11CNYUpdated Oct 21, 2026
Avg 10-Day Volume
37.45MSharesUpdated Oct 21, 2026
Avg 30-Day Volume
23.38MSharesUpdated Oct 21, 2026
Diluted EPS (TTM)
0.1000CNYUpdated Oct 21, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Dividend several times the last twelve months' earningsSignificant
Payout Ratio: 3.58Dividend per Share: 0.35Earnings per Share: 0.10
Financial Health
Altman Z-Score 3.72: safe zoneNotable
Altman Z-Score: 3.72
Supply Chain
Upstream position: supplies 5 industries, depends on 1Notable
Outgoing: 5.00Incoming: 1.00
Scale
Market cap is $1.2B, above the global median of $1.14BNotable
Market cap (USD): 1,200,798,383.382Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.